Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2291-2297

  Larbig, M ^a   Mansouri, E ^b   Freihorst, J ^a   Tummler B ^a   Kohler G ^c   Domdey, H ^d   Knapp, B ^e   Hungerer, K D ^e   Hundt, E ^e   Gabelsberger, J ^d   Von Specht, B U ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Chiron Behring GmbH & Co   (Germany)

Author keywords

Human volunteers; Mucosal vaccine; P. aeruginosa outer membrane proteins

Indexed keywords

CHELATE; DODECYL SULFATE SODIUM; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NATRIUMLAURYL SULFATE; NICKEL; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN F[190-342][HISTIDINE 6]; OUTER MEMBRANE PROTEIN I[21-83]; PYROGEN; SULFUR DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY DETECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG PURITY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RAT; VACCINE PRODUCTION;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MICE; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYROGENS; RATS; RECOMBINANT PROTEINS; SAFETY;

EID: 0035925682     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00550-8     Document Type: Conference Paper

References (42)

1. Pseudomonas bacteremia in a community teaching hospital, 1989-1984
2. Secular trends in nosocomial bloodstream infections in a 55-bed cardiothoracic intensive care unit
3. Pseudomonas immunotherapy
4. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center
5. Opportunistic infections in severely burned patients
6. Burn wound infections: Current status
7. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: An emerging problem
8. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital
9. Nosocomial infections in an oncology intensive care unit
10. High incidence of antibiotic resistance among bacteria in 4 intensive care units at a university hospital in Sweden
11. Intrinsic antibiotic resistance of Pseudomonas aeruginosa
12. Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: Experimental studies in animals
13. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain. 1998
14. Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11
15. Antibiotics and Pseudomonas aeruginosa
16. Immunization against Pseudomonas infection after thermal injury
17. Controlled trials of a poly-valent Pseudomonas vaccine in burns
18. A new polyvalent Pseudomonas vaccine
19. Octavalent Pseudomonas aeruginosa-O-polysaccharide-toxin A conjugate vaccine
20. Safety and immunogenicity of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans
21. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
22. Outer membrane proteins of P. aeruginosa serotype strains
23. Safety and immunogenicity of high-molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa
24. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research
25. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine
26. Rational for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients
27. Naked DNA points way to vaccines
28. Immunization with polynucleotides
29. Molecular and cellular basis of immune protection of mucosal surfaces
30. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection
31. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli
32. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies
33. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in rats
34. Use of purified outer membrane protein F (porin) of Pseudomonas aeruginosa as a protective vaccine in mice
35. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model
36. Protection immunocompromised mice against lethal infection with P. aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins
37. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene
38. Pseudomonas aeruginosa outer membrane lipoprotein I gene: Molecular cloning sequence, and expression in Escherichia coli
39. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers
40. Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections
41. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers